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Scope: Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic 
candidate for the treatment of obesity. Since FGF21 production is regulated by various 
nutritional factors, we analyze the impact of low protein intake on circulating levels of 
this growth hormone in mice and in a sub cohort of the PREDIMED (Prevención con 
Dieta Mediterránea) trial. We also describe the role of hepatic FGF21 in metabolic 
adaptation to a low-protein diet (LPD).  
Methods and results: We fed control and liver-specific Fgf21 knockout (LFgf21KO) 
mice a LPD. This diet increased FGF21 production by inducing its overexpression in 
liver, and this correlated with a body weight decrease without changes in food intake. 
The LPD also caused FGF21-dependent browning in subcutaneous white adipose 
tissue (scWAT), as indicated by an increase in the expression of uncoupling protein 1 
(UCP1). In a subgroup of 78 individuals from the PREDIMED trial, we observed an 
inverse correlation between protein intake and circulating FGF21 levels.  
Conclusions: Our results reinforce the involvement of FGF21 in coordinating energy 
homeostasis under a range of nutritional conditions. Moreover, here we describe an 
approach to increase the endogenous production of FGF21 in humans that may pave 
the way for a treatment for obesity. 
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FGF21 (Fibroblast growth factor 21) is considered a promising therapeutic candidate 
for the treatment of obesity and type-2 diabetes. Its administration to obese rodents 
and monkeys leads to decreased plasma concentrations of glucose, insulin, 
triglycerides and cholesterol, as well as a reduction in body weight through increased 
energy expenditure (EE) [1]. The injection of FGF21 in experimental animals induces 
increased thermogenic capacity by stimulating the expression of uncoupling protein 1 
(UCP1) and type 2 iodothyronine deiodinase protein 2 (DIO2) in brown adipose tissue 
(BAT), and UCP1 in white adipose tissue (WAT), where it produces the so-called 
browning process [2,3]. Although most of the effects of FGF21 have been related to 
UCP1 expression, it has also been reported that Ucp1-null mice respond positively to 
the pharmacological administration of this growth factor [4,5].    
FGF21 is a member of the FGF family, which is characterized by endocrine properties. 
It is produced mainly by the liver, but also by other tissues such as WAT, BAT, skeletal 
muscle, and pancreas [6–9]. Hepatic FGF21 expression is induced by fasting, and its 
transcriptional activity is  tightly controlled by peroxisome proliferator-activated receptor 
alpha (PPARa) [10–13].  The expression of this growth factor in liver activates fatty 
acid oxidation (FAO), ketogenesis and gluconeogenesis in this organ, thereby 
triggering a metabolic state that mimics long-term fasting [14].  
In addition to fasting, FGF21 expression is also induced in various tissues in response 
to a number of nutritional challenges and also to cold exposure. In this regard, FGF21 
expression in BAT is produced in response to cold temperature [9,15], although it is 
unclear whether BAT-derived FGF21 acts as an endocrine factor or whether it is simply 
an autocrine factor in the adipose tissue itself. 
In mouse liver and HepG2 cells, FGF21 is induced by leucine-deprivation as part of the 
transcriptional program initiated by increased levels of activating transcription factor 4 
(ATF4) [16]. The ATF4-dependent increase in FGF21 expression has been confirmed 
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in mice with autophagy deficiency in skeletal muscle and in liver [17]. Interestingly, 
these mice are protected from diet-induced obesity (DIO) and insulin resistance. The 
similarities in the metabolic responses between the effects to leucine-deprivation [18] 
and to FGF21 overexpression allowed us to consider FGF21 as a key mediator 
between amino acid deprivation and lipid metabolism in liver, WAT and BAT. In this 
regard, results from the evaluation of the metabolic response of Fgf21-deficient mice to 
a leucine-deficient diet previously led us to conclude that, as expected, most of the 
effects caused by leucine deprivation in liver, WAT and BAT are impaired in the 
absence of this growth factor [19].  
Likewise, methionine-deprived mice show a phenotype comparable to that of leucine-
deprivation, including resistance to a high-fat diet (HFD), improved glucose 
homeostasis, increased fatty acid activation and FAO in liver, enhanced lipolysis in 
WAT, and increased UCP1 expression in BAT [20,21]. Of note, the induction of hepatic 
FGF21 expression under leucine- or methionine-restricted diets was found to be 
accompanied by an increase in FGF21 protein levels in serum.  
In order to facilitate the translation of these findings to humans, here we focussed on 
low-protein diets (LPD) instead of amino acid-deficient diets. Protein restriction brings 
about weight loss and an increase in both food intake and EE [22]. Moreover, a LPD 
induces thermogenic markers in BAT of obese rats [23]. Moreover, serum 
concentrations of FGF21 in both rodents and humans increase upon exposure to a 
LPD, regardless of total calorie intake. This observation thus reveals that FGF21 is 
likely to be involved in the metabolic response to protein-restricted diets [24].  
Here we addressed whether a LPD exerts similar effects on lipid metabolism to those 
of a leucine-deficient diet and whether these effects are dependent on hepatic FGF21 
production. To this end, we examined the metabolic response of wild-type and Fgf21 
liver-specific knockout mice (LFgf21KO) to a LPD (up to 5% of energy as protein). A 
decreased in dietary protein content induced a huge increase in FGF21 serum levels, 
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significant weight loss, and an increase in the expression of UCP1 in the subcutaneous 
WAT (scWAT) of wild-type mice. Remarkably, no effects were observed in Fgf21-
deficient mice, thereby indicating that the absence of FGF21 blunts or completely 
blocks the response to a LPD in this mouse model .  
To corroborate these results in humans, we evaluated whether protein intake is 
associated with circulating levels of FGF21. We calculated protein intake through 
nutritional questionnaires and determined the serum levels of FGF21 in 78 individuals 
randomly selected from two nodes of the PREDIMED (Prevención con Dieta 
Mediterránea) trial. As with the animal model, an inverse correlation between 
circulating FGF21 levels and protein intake was observed.  
To summarize, here we define the molecular mechanisms by which a LPD exerts its 
metabolic effects through the induction of hepatic FGF21 expression and browning of 
scWAT. Furthermore, the data collected from humans raises the possibility of an 
alternative approach to modulate the FGF21 circulating levels instead of its 
pharmacological administration. In this regard, we propose the modification of protein 
intake to enhance FGF21 production.  
MATERIAL AND METHODS 
Animals.  
To generate the LFgf21KO mice, Fgf21loxP mice (Fgf21tm1.2Djm/J) that have Fgf21 
flanked by two loxP sites (Jackson Laboratory, USA) were crossed with Albumin-cre 
(Tg(Alb1-cre)1Dlr/J) mice (kindly provided by Dr. A. Zorzano). The latter express the 
CRE recombinase enzyme under control of albumin promoter/enhancer elements, thus 
allowing liver-specific gene deletions [25]. Fgf21LoxP mice were used as controls. 
Animals were housed in a temperature-controlled room (22±1°C) on a 12/12 h 
light/dark cycle and were provided free access to commercial rodent chow and tap 
water prior to the experiments.  
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The control diet (CD) (Ref. D10001) and LPD (Ref. D12010401) were obtained from 
Research Diets, Inc. (USA). Both diets were isocaloric. They had the following 
composition (in percentage of mass): 20% protein, 66% carbohydrates and 5% fat for 
the CD, and 5% protein, 81% carbohydrates and 5% fat for the LPD (detailed 
composition shown in Table S1). For the feeding experiment, 8-week-old male mice 
were first fed the CD for 7 days and then randomly assigned to either the CD or LPD 
group with free access to food and water for 7 days. Food intake and body weight were 
recorded daily. Animals were then anesthetized by isoflurane inhalation, and blood was 
collected by cardiac puncture. After euthanizing the animals, tissues were isolated and 
immediately snap-frozen and stored at −80°C for future analysis. The Animal Ethics 
Committee of the University of Barcelona approved these experiments (CEEA register: 
48/15) 
Human samples for plasma measurements. 
We used plasma samples from 78 men and women randomly selected from the 
participants of the centers in Hospital Clinic (Barcelona) and Reus (Tarragona) of the 
PREDIMED trial (www.predimed.es). This study was a 5-year randomized clinical trial 
to compare the effects of either a Mediterranean diet supplemented with extra virgin 
olive oil or nuts versus a low-fat control diet. A total of 7447 asymptomatic men but at 
high cardiovascular risk (aged 55–80 years) and women (aged 60–80 years) were 
recruited. All participants had type 2 diabetes or three or more cardiovascular risk 
factors. Details of the recruitment method and study design have been described 
elsewhere [26] and are also available at www.predimed.es. In addition to the plasma 
samples, we also gathered information from these 78 individuals, including a 137-item 
semi-quantitative food frequency questionnaire (FFQ), and a general questionnaire that 
provided data on lifestyle habits, concurrent diseases, anthropometry, and medication 
use. Total energy intake and nutrient intake were calculated on the basis of Spanish 
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food composition tables [27]. The study protocol was approved by the institutional 
review boards of the participating centers (ISRCTN35739639).  
Plasma measurements.  
Mouse plasma samples were obtained by centrifuging whole blood collected in EDTA-
treated tube. The plasma was stored at −80°C. FGF21 in mouse and human plasma 
was measured by means of a Human (ref. EZHFGF21-19K) and Mouse/Rat (ref. 
EZRMFGF21-26K) FGF21 ELISA obtained from EMD Millipore (Germany). The assay 
was conducted following the manufacturer's protocol. Briefly, a calibration curve was 
constructed by plotting the difference in absorbance values at 450 and 590 nm versus 
the FGF21 concentrations of the calibrators, and concentrations of unknown samples 
(performed in duplicate) were determined using this calibration curve.  
RNA isolation and relative quantitative RT-PCR 
Total RNA was extracted from the frozen tissues [liver, epididymal WAT (eWAT), BAT 
and inguinal scWAT] using TRI reagent solution (ref. AM9738 Ambion, Thermo Fisher 
Scientific, USA) followed by DNase I treatment (ref. AM1906, Ambion, Thermo Fisher 
Scientific, USA) to eliminate genomic DNA contamination. To measure the relative 
mRNA levels, quantitative (q)RT-PCR was performed using SYBR Green or TaqMan 
reagents. cDNA was synthesized from 1 µg of total RNA by MLV reverse transcriptase 
(ref. 28025021, Invitrogen, Thermo Fisher Scientific, USA) with random hexamers (ref. 
11034731001, Roche Diagnostics, Germany), following the manufacturer's instructions. 
The TaqMan Gene Expression Master Mix (ref. 4369514) and SYBR® Green PCR 
Master Mix (ref. 4364344), supplied by Applied Biosystems (ThermoFisher Scientific, 
USA), were used for the PCR step.  Amplification and detection were performed using 
the Step-One Plus Real-Time PCR System (Applied Biosystems, ThermoFisher 
Scientific, USA). Each mRNA from a single sample was measured in duplicate, using 
18S, Beta-Actin, and 36b4 as housekeeping genes. The primer sequences are shown 
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in supplemental information Table S2. Results were obtained by the Relative Standard 
Curve Method and expressed as fold increase versus the experimental control. 
Protein extracts preparation. 
To obtain liver nuclear extracts, frozen liver was triturated with a mortar in liquid 
nitrogen and immediately homogenized with a Dounce in 1 ml of HB buffer [15 mM 
Tris-HCl (pH 8), 15 mM NaCl, 60 mM KCl, 0.5 mM EDTA], and centrifuged at 800 g for 
5 min. The resulting pellet was resuspended in 100 µl of HB buffer supplemented with 
0.05% Triton X-100 (Sigma, USA) and centrifuged for 10 min at 1,000 g. Nuclear 
pellets were washed with 1 ml of HB buffer supplemented with 0.05% Triton X-100 and 
1 ml of HB buffer. Nuclei were incubated at 4°C for 30 min in 50 µl of HB buffer 
containing 360 mM of KCl and then centrifuged for 5 min at 10,000 g. The 
supernatants corresponding to the nuclear extracts were collected, frozen, and stored 
at −80°C. Protein concentration was determined using the Bio-Rad Protein Assay Dye 
Reagent Concentrate (Ref. 5000006, Bio Rad, USA). All buffers were supplemented 
with a mixture of protease inhibitors (Ref. P8340, Sigma-Aldrich, USA), 0.1 mM of 
PMSF, and a phosphatase inhibitor cocktail 3 (Ref. P0044, Sigma-Aldrich, USA). 
Immunoblotting. 
Nuclear proteins were resolved by SDS-polyacrylamide gel electrophoresis and 
transferred onto a Hybond-P PVDF membrane (Millipore). Membranes were blocked 
(Tris-HCl 50 mM pH 8, 150 mM, 5% skimmed milk, 0.1% Tween) for 1 h at room 
temperature. The blots were then incubated with ATF4 primary antibody (sc-200, Santa 
Cruz Biotechnology, Inc, USA) in blocking solution (1:200). After an overnight 
incubation at 4°C, the blots were washed and incubated with an anti-rabbit horseradish 
peroxidase-conjugated secondary antibody (ref. NA934, Amersham, GE Healthcare, 
UK) in blocking buffer for 2 h at room temperature. The blots were developed using the 
EZ-ECL Chemiluminescence Detection Kit for HRP (ref. 20-500-500, Biological 
Industries, Israel). Quantification was performed using Image J software. 
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Data analysis / statistics. 
For human samples, baseline characteristics are presented as means ± standard error 
of the mean (SEM) for continuous variables, frequencies and percentages for 
categorical variables across quartiles of protein intake at baseline. Differences between 
quartiles were tested by a 1-factor ANOVA test for continuous variables and by the chi-
square test for the categorical ones. We performed multiple linear regressions to 
evaluate the relationship between protein intake (exposure variable) and FGF21 
hormone levels (dependent variable). Protein intake was previously adjusted for 
calories using the residual method. Regression analyses were unadjusted (model 1) or 
adjusted by body mass index (BMI) and total energy intake (model 2) 
All statistical analyses were conducted using SAS software, version 9.3 (SAS Institute, 
Inc., USA). All t tests were 2-sided and P values below 0.05 were considered 
statistically significant. 
RESULTS AND DISCUSSION 
A LPD induces FGF21 gene expression in the liver of control mice, but not in 
BAT or WAT.  
According to previously reported results, mice on a LPD show a dramatic increase in 
serum levels of FGF21 [22–24] (Figure 1A). To check the origin of this FGF21, we 
analyzed the Fgf21 mRNA levels in several tissues. The liver is the main site of FGF21 
production and release into the blood. Accordingly, we observed a great induction of 
Fgf21 mRNA synthesis in the liver of mice on the LPD (Figure 1B). This increase 
correlated positively with serum levels. In contrast, Fgf21 expression was unchanged in 
BAT, eWAT and scWAT of control mice (Fgf21loxP) on the same diet (Figure 1C).  
To determine the specific role of hepatic FGF21 in the metabolic response to a LPD, 
we fed LFgf21KO mice a LPD diet. As expected, Fgf21 mRNA levels were 
undetectable in the livers of these animals (Figure 1B), while no statistically significant 
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changes were detected in BAT, eWAT or scWAT when compared to the same tissues 
in control mice (Figure 1C).  
This mouse model shows that protein restriction almost exclusively affects the hepatic 
expression of FGF21 and that there is no compensatory response in other tissues, 
such as BAT or WAT.  
A LPD increases ATF4 protein levels in mouse liver.  
GCN2 is a kinase that acts as a sensor of amino acid supply [28]. When activated, 
GCN2 phosphorylates EIF2a, which results in the slowing or stalling of the initiation 
step of mRNA translation. Hence, phospho-EIF2a reduces general protein synthesis 
rates. Paradoxically, in these circumstances there is an increase in the translation of 
discrete mRNAs, including ATF4 [29,30]. A LPD increases GCN2-dependent 
phosphorylation of eIF2a, resulting in greater levels of ATF4 protein [31,32]. ATF4 is a 
transcriptional factor that directly or indirectly induces a subset of specific genes to 
regulate metabolic adaptation to amino acid restriction. The 5’ region of Fgf21 contains 
two evolutionarily conserved functional ATF4-binding sequences responsible for its 
ATF4-dependent transcriptional activation [16,33]. To determine the effect of a LPD on 
ATF4 expression, we analyzed liver protein extracts of mice fed a LPD or a CD for 7 
days. ATF4 expression was induced in liver in response to the LPD, as revealed by 
Western blot assays (Figure 2A-B). These results are consistent with previous 
published data reporting that ATF4 triggers the expression of FGF21 and that Gcn2 -/- 
mice show a partially blunted induction of FGF21 under protein restriction [24]. On the 
basis of the aforementioned published data, our results support the notion that the 
GCN2-ATF4 pathway is likely to be the main mechanism underlying hepatic FGF21 
overexpression upon protein restriction.  
GCN2-independent mechanisms that induce hepatic FGF21 in response to 
methionine-restricted diets have recently been described [34]. This observation points 
to a different response program in liver via a non-canonical PERK/nuclear respiratory 
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factor 2 (NRF2) pathway. This alternative pathway could effectively sense and 
translate the metabolic responses to methionine restriction in the absence of GCN2. In 
parallel, the absence of GCN2 during long-term dietary protein restriction has been 
reported to be compensated upstream of ATF4 to induce FGF21 [35]. Globally, the 
impact of alternative pathways to stimulate FGF21 expression under a LPD, whether 
they involve ATF4 or not, should be addressed in greater depth.  
Fgf21 deficiency significantly attenuates weight loss under a LPD 
Mice fed a LPD presented rapid weight loss. Here we addressed whether this 
phenomenon is dependent on hepatic FGF21. For this purpose, Fgf21LoxP mice and 
LFgf21KO mice were fed a CD or LPD for 7 days. 
Our data showed that weight loss was partially blunted in LFgf21KO mice (Figure 3A-
B). However, the reduction in food intake observed under a LPD was unchanged 
between genotypes (Figure 3C). It is remarkable that these results contradicted 
previous publications describing either no change or an increase in food intake in 
response to protein restriction [24]. Nonetheless, the present results are consistent with 
the decreased food intake described in mice fed leucine-deficient diets [19]. Minor 
changes in diet composition affecting amino acid bioavailability may explain these 
discrepancies. Moreover, although FGF21 has the potential to modulate food 
preferences [36,37]. In our mouse model this FGF21 did not contribute to the food 
aversion caused by the LPD. 
To determine the importance of each tissue in overall weight loss, we calculated the 
change in weight of individual tissues. All tissues analyzed tended to weigh less in 
mice on the LPD, reaching statistical significance in heart, liver, scWAT and p=0.06 in 
eWAT (Figure 4). Regarding the role of FGF21, our results show that the weight loss 
observed in scWAT and heart was dependent on hepatic FGF21 expression, as weight 
loss was blunted in LFgf21KO mice under the same diet. The effect of the LPD on liver 
tissue weight was partially abolished by hepatic Fgf21 deficiency (Figure 4).   
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Taken together, FGF21 produced by the liver is, at least in part, responsible for the 
body weight loss experienced by the mice on the LPD. Our results point to scWAT as 
one of the target tissues of hepatic FGF21 regarding the weight loss effect. Since 
hepatic FGF21 exerts its effects mainly in WAT and BAT through regulating lipid 
metabolism, the following experiments are focused on describing the role of LPD-
induced FGF21 on the metabolic response of adipose depots. 
LPD induces metabolic changes in response to FGF21 in scWAT, but not in 
eWAT or BAT.  
Thermogenesis in BAT is mediated by the upregulation of UCP1 [38]. It has been 
proposed that the induction of FGF21 production by the liver mediates direct activation 
of brown fat thermogenesis during the fetal-to-neonatal transition [39]. FGF21 also 
regulates peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1a) and browning of WAT in adaptive thermogenesis [40]. 
Contrary to what happens under leucine deprivation [19], no statistically significant 
induction of Ucp1 or Dio2 mRNA levels were observed in BAT or eWAT of control mice 
under the LPD (Figure 5A-B). In contrast, the analysis of gene expression in scWAT 
revealed that the LPD induced the expression of Ucp1, Pgc1a, Cidea and PR domain 
containing 16 (Prdm16), reaching a statistically significant value for Ucp1 and Pgc1a 
(Figure 6). This expression pattern was not detected in the LFgf21KO mice (Figure 6), 
thereby indicating the role of FGF21 in the metabolic adaptation of scWAT to protein 
restriction 
As UCP1 activity is related to EE, the blunted induction of UCP1 in the LFgf21KO mice 
under LPD may contribute to the lower weight loss observed in this mouse model 
under these circumstances. In conclusion, hepatic FGF21 induces the browning of 
scWAT and increases the thermogenic capacity of mice on a LPD. 
FGF21 plasma levels correlate negatively with protein intake in humans.  
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To translate our results to humans, we evaluated the relationship between protein 
intake and circulating levels of FGF21 in 78 individuals randomly selected from the 
PREDIMED trial. Baseline data for these subjects are shown in Table 1. Protein intake 
was obtained from FFQs and was expressed as grams of protein per day (g/day). We 
used baseline samples (T=0). Results from the multiple linear regression analyses 
showed a significant inverse relationship between plasma FGF21 concentrations and 
dietary intake of protein. At baseline, FGF21 levels decreased by 3.39 pg/mL for each 
gram of protein ingested (Table 2). The participants with a high intake of protein 
showed statistically significant lower values of circulating FGF21.   
We also performed regression analyses using quartiles of protein intake and obtained 
similar results. After adjustment for BMI and total energy intake, FGF21 decreased (-
30.7 pg/mL) when moving from the lower to higher quartiles (p=0.015) (Figure 7).   
Similarly to the data from mice, these results indicate that the serum concentrations of 
FGF21 are inversely proportional to dietary protein intake. 
CONCLUDING REMARKS  
Here we addressed the role of hepatic FGF21 in the metabolic changes triggered by a 
LPD. Our results demonstrate that the effects of a LPD depend, at least in part, on the 
circulating levels of FGF21 and consequently on the liver production of this growth 
factor. The LFgf21KO mice revealed the relevance of FGF21 in the response to a LPD, 
but also in the metabolic and transcriptional pathways activated or repressed by protein 
restriction. 
Given the consistency between the results of our study in humans and those in mice, 
we postulate that dietary protein content is crucial for the modulation of circulating 
FGF21 levels and thus for the activity of this hormone in target tissues. We propose a 
dietary intervention consisting of a reduction in protein intake as a non-invasive 
approach to induce the hepatic expression of FGF21. We also describe the molecular 
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mechanisms through which a LPD—via FGF21—could be beneficial to restore 
lipid/glucose homeostasis.  
Studies performed in humans provide contradictory results regarding the correlation 
between plasma levels of FGF21, BMI, and insulin resistance [41–43]. Also, the 
FGF21-resistant state described in mice [44] is not well established in humans and the 
beneficial effects of FGF21 induction have yet to be demonstrated in the latter. 
Our findings provide new insight into the modulation of dietary protein as a strategy to 
induce elevated serum concentrations of FGF21. Further studies will be needed to 
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Table 1. Baseline characteristics of participants from the PREDIMED cohort included 
in this study, divided into quartiles of energy-adjusted protein intake at baselinea 
 Quartiles of energy-adjusted protein intake  
 Q1 Q2 Q3 Q4 P valueb 
No subjects (78) 19 20 20 19  
Age (years) 67.1±5.9 65.7±4.8 67.0±6.4 65.3±4.0 0.30 
Sex (women) 6 (31) 10 (50) 9 (45) 15 (79) 0.03 
Body mass index 
(Kg/m2) 
28.1±3.2 30.0±3.4 27.7±2.7 30.8±2.9 
0.006 
Energy intake (Kcal/d) 2370±350 2192±603 2227±433 2390±571 0.51 
Protein intake (g/day) 80±6 90±2 97±3 110±5 <0.0001 
FGF21 (pg/mL) 289±116 276±143 256±117 190±115 0.07 
aCategorical variables: subjects (percentage), continuous variables: mean ± SD 
bOne-way ANOVA tests (continuous variables) or chi-squared tests (categorical 
variables). 
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Table 2. Multivariable regression analyses with FGF21 (pg/mL) as dependent variable 
and energy-adjusted protein intake at baseline (g/day) as independent variable.  
   βa P value 95% CI 
Protein intake (continuous variable) Model 1b -3.42 0.006 -5.83,-1.02 
 Model 2c -3.39 0.007 -5.86, -0.92 
Quartiles of protein intake Model 1b -31.5 0.01 -56.5, -6.5 
 Model 2c -30.8 0.02 -56.5, -5.0 
CI: Confidence Interval. 
aParameter estimates. 
bUnadjusted. 
cAdjusted for body mass index (BMI) and total energy intake. 
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Figure 1. FGF21 is induced by a LPD in liver but not in BAT or WAT, and this induction correlates 
positively with plasma concentration in mice. Plasma protein concentration of FGF21 was measured by 
ELISA (A). Fgf21 mRNA levels in liver (B) and WAT and BAT (C) were measured by qRT-PCR. Error bars 
represent the mean ± SEM. ** p<0.01 ***p<0.001 versus Fgf21LoxP mice fed a CD (n=7–9/group).  
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Figure 2. A LPD increases ATF4 protein levels in liver. ATF4 protein levels were determined by Western 
blot analysis using hepatic nuclear extracts obtained from Fgf21LoxP mice administered a CD or LPD (A). The 
experiment was normalized by actin protein levels as loading control and the intensity of the bands were 
quantified by densitometry with the Image J software (B). Error bars represent the mean ± SEM. ** p<0.01 
versus CD. (n=3/group).  
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Figure 3. Hepatic FGF21 expression is required for the weight loss caused by LPD but does not 
affect food consumption. Body weight progression of mice fed a CD or LPD expressed as percentage of 
the initial weight, which was considered 100% (A). Total body weight change (g) after 7 days on a CD or 
LPD (B). Daily food intake (C). Error bars represent the mean ± SEM. ** p<0.01 versus Fgf21LoxP mice fed a 
CD, # p<0.05 versus LFgf21KO fed a CD; 0.07 represents p value versus LFgf21KO mice fed a CD (n=7–
9/group).  
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Figure 4. Hepatic FGF21 is required for the weight loss caused by a LPD. The weight of heart, liver, 
eWAT, scWAT, BAT and gastrocnemius in mice fed a CD or LPD is presented as the mg of tissue per 100 mg 
of total body weight. Error bars represent the mean ± SEM. * p<0.05 *** p<0.001 versus Fgf21LoxP mice 
fed a CD; # p<0.05 ## p<0.01 versus LFgf21KO mice fed a CD; 0.06 represents the p value with respect to 
Fgf21LoxP mice fed a CD (n=7–9/group).  
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Figure 5. A LPD does not alter thermogenic genes in BAT or eWAT. Ucp1 and Dio2 expression was 
measured by qRT-PCR in mouse BAT and eWAT. Error bars represent the mean ± SEM. * p<0.05 versus 
Fgf21LoxP mice fed a CD (n=7–9/group).  
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Figure 6. Hepatic FGF21 is required for inducing thermogenic gene expression during a LPD. Ucp1, 
Dio2, Pgc1a, Pparg, Prmd16 and Cidea expression was measured by qRT-PCR in mouse scWAT. Error bars 
represent the mean ± SEM. * p<0.05 versus Fgf21LoxP mice fed a CD (n=7–9/group).  
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Figure 7. Circulating FGF21 levels correlate negatively with protein intake. Plasma FGF21 
concentration divided into quartiles of protein intake adjusted for the calorie intake of 78 participants in the 
PREDIMED trial. Error bars represent the mean ± SEM. * p<0.05 from 1st quartile; # p<0.05 from the 2nd 
 quartile.   
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In mice, a low protein diet induces a huge increase in liver FGF21 expression 
and serum levels, which correlates with enhanced ATF4 protein levels. Also, 
this diet caused an FGF21-dependent browning of subcutaneous white adipose 
tissue. The observation of an inverse relationship between serum levels of 
FGF21 and dietary protein content also in humans suggests that the induction 
of hepatic FGF21 expression by a low protein diet could offer an effective 
treatment for obesity and type 2 diabetes. 
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